Vaccination against atherosclerosis: An overview

Ross, 1999, Atherosclerosis — An Inflammatory Disease — NEJM, New Engl J Med, 340115 Libby, 2013, Immune Effector Mechanisms Implicated in Atherosclerosis: From Mice to Humans, Immunity, 10.1016/j.immuni.2013.06.009 Naghavi, 2017, Global, regional, and national age-sex specifc mortality for 264 causes of death, 1980–2016: A systematic analysis for the Global Burden of Disease Study 2016, Lancet, 10.1016/S0140-6736(17)32152-9 Baingana, 2006, Changing patterns of disease and mortality in Sub-Saharan Africa: an overview Robertson, 2006, T cells in atherogenesis: For better or for worse?, Arterioscler Thromb Vasc Biol, 10.1161/01.ATV.0000245830.29764.84 Hansson, 2006, The immune response in atherosclerosis: A double-edged sword, Nat Rev Immunol, 10.1038/nri1882 Tedgui, 2006, Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways, Physiol Rev, 10.1152/physrev.00024.2005 Uyttenhove, 2004, Development of an anti-IL-12 p40 auto-vaccine: Protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection, Eur J Immunol, 10.1002/eji.200425443 Delavallée, 2008, Early and long-lasting protection from arthritis in tumour necrosis factor α (TNFα) transgenic mice vaccinated against TNFα, Ann Rheum Dis Röhn, 2006, Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis, Eur J Immunol, 10.1002/eji.200636658 Melero, 2014, Therapeutic vaccines for cancer: An overview of clinical trials, Nat Rev Clin Oncol, 10.1038/nrclinonc.2014.111 Kimura, 2015, Vaccination to modulate atherosclerosis, Autoimmunity, 10.3109/08916934.2014.1003641 Ambühl, 2007, A vaccine for hypertension based on virus-like particles: Preclinical efficacy and phase I safety and immunogenicity, J Hypertens, 10.1097/HJH.0b013e32800ff5d6 Lambracht-Washington, 2013, Advances in the development of Vaccines for Alzheimer's Disease Ongoing Clinical Immunotherapy Trials, Discov Med, 15, 319 Spohn, 2014, Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes, Mol Ther Methods Clin Dev, 10.1038/mtm.2014.48 Wildbaum, 2014, A Targeted DNA Vaccine Augments the Natural Immune Response to Self TNF- and Suppresses Ongoing Adjuvant Arthritis, J Immunol Youssef, 1999, Prevention of experimental autoimmune encephalomyelitis by MIP-1α and MCP-1 naked DNA vaccines, J Autoimmun, 10.1006/jaut.1999.0306 Palinski, 1995, Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis (modified lipoproteins/oxidation/autoantibodies/atherosclerosis/immune system), Med Sci, 92, 821 Ameli, 1996, Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits, Arterioscler Thromb Vasc Biol, 10.1161/01.ATV.16.8.1074 Galley, 2004, Physiology of the endothelium, Br J Anaesth, 10.1093/bja/aeh163 Landmesser, 2004, Endothelial Function: A Critical Determinant in Atherosclerosis?, Circulation, 10.1161/01.CIR.0000129501.88485.1f Schächinger, 1999, A positive family history of premature coronary artery disease is associated with impaired endothelium-dependent coronary blood flow regulation, Circulation, 10.1161/01.CIR.100.14.1502 Napoli, 2006, Nitric oxide and atherosclerosis: An update, Nitric Oxide Biol Chem, 10.1016/j.niox.2006.03.011 Teplyakov, 2004, Endothelin-1 involved in systemic cytokine network inflammatory response at atherosclerosis, J Cardiovasc Pharmacol, 10.1097/01.fjc.0000166283.01034.c6 Iwasa, 1999, Increased immunoreactivity of endothelin-1 and endothelin B receptor in human atherosclerotic lesions. A possible role in atherogenesis, Atherosclerosis, 10.1016/S0021-9150(99)00134-3 Cybulsky, 2001, A major role for VCAM-1, but not ICAM-1, in early atherosclerosis, J Clin Investig, 10.1172/JCI11871 Collins, 2000, P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice, J Exp Med, 191, 189, 10.1084/jem.191.1.189 Nageh, 1997, Deficiency of inflammatory cell adhesion molecules protects against atherosclerosis in mice, Arterioscler Thromb Vasc Biol, 10.1161/01.ATV.17.8.1517 Shih, 1999, Blocking very late antigen-4 integrin decreases leukocyte entry and fatty streak formation in mice fed an atherogenic diet, Circ Res, 10.1161/01.RES.84.3.345 Mach, 1999, Differential expression of three t lymphocyte-activating CXC chemokines by human atheroma-associated cells, J Clin Investig, 10.1172/JCI6993 Qiao, 1997, Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice, Am J Pathol, 150, 1687 Thomas Van, 2009 Lefkowitz, 2001, Prospects for cardiovascular research, J Am Med Assoc, 10.1001/jama.285.5.581 Libby, 2002, Inflammation and atherosclerosis 28, Circulation, 105, 1135, 10.1161/hc0902.104353 Ridker, 1998, Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men, Lancet, 10.1016/S0140-6736(97)09032-6 Herity, 1999, Clinical aspects of vascular remodeling, J Cardiovasc Electrophysiol, 10.1111/j.1540-8167.1999.tb01273.x Lee, 2001, Mechanical Strain Induces Specific Changes in the Synthesis and Organization of Proteoglycans by Vascular Smooth Muscle Cells, J Biol Chem, 10.1074/jbc.M010556200 Davies, 1990, A macro and micro view of coronary vascular insult in ischemic heart disease, Circulation, 82, II38 Schönbeck, 1997, Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: A role for CD40 signaling in plaque rupture?, Circ Res, 10.1161/01.RES.81.3.448 Libby, 2001, Current concepts of the pathogenesis of the acute coronary syndromes, Circulation, 104, 365, 10.1161/01.CIR.104.3.365 Naruko, 2002, Neutrophil infiltration of culprit lesions in acute coronary syndromes, Circulation, 10.1161/01.CIR.0000042674.89762.20 Sun, 2007, Mast cells promote atherosclerosis by releasing proinflammatory cytokines, Nat Med, 10.1038/nm1601 Bot, 2015, Mast cells as effectors in atherosclerosis, Arterioscler Thromb Vasc Biol, 10.1161/ATVBAHA.114.303570 Bobryshev, 1998, Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reaction, Cardiovasc Res, 10.1016/S0008-6363(97)00229-0 Whitman, 2004, Depletion of natural killer cell function decreases atherosclerosis in low-density lipoprotein receptor null mice, Arterioscler Thromb Vasc Biol, 10.1161/01.ATV.0000124923.95545.2c Cybulsky, 1991, Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis, Science (80–), 10.1126/science.1990440 Zhou, 2000, Transfer of CD4+T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice, Circulation, 10.1161/01.CIR.102.24.2919 Van Wanrooij, 2005, HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice, Arterioscler Thromb Vasc Biol, 10.1161/01.ATV.0000192018.90021.c0 Jonasson, 2011, Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque, Arterioscler An Off J Am Hear Assoc Inc Elhage, 2003, Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice, Cardiovasc Res, 10.1016/S0008-6363(03)00343-2 Hauer, 2005, Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis, Circulation, 10.1161/CIRCULATIONAHA.104.533463 Frostegård, 1999, Cytokine expression in advanced human atherosclerotic plaques: Dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines, Atherosclerosis, 10.1016/S0021-9150(99)00011-8 Brånén, 2004, Inhibition of tumor necrosis factor-α reduces atherosclerosis in apolipoprotein E knockout mice, Arterioscler Thromb Vasc Biol, 10.1161/01.ATV.0000143933.20616.1b Buono, 2003, Influence of interferon-γ on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse, Arterioscler Thromb Vasc Biol, 10.1161/01.ATV.0000059419.11002.6E Sakaguchi, 1995, Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases, J Immunol, 10.4049/jimmunol.155.3.1151 Hsieh, 2004, Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors, Immunity, 21, 267, 10.1016/j.immuni.2004.07.009 Rao, 2007, Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall, Circ Res, 10.1161/CIRCRESAHA.107.151860b Boring, 1998, Decreased lesion formation in CCR2(-/-) mice reveals a role for chemokines in the initiation of atherosclerosis, Nature, 10.1038/29788 Guo, 2005, The presence of leukocyte CC-chemokine receptor 2 in CCR2 knockout mice promotes atherogenesis, Biochim Biophys Acta Mol Basis Dis, 10.1016/j.bbadis.2004.10.007 Fontenot, 2005, A well adapted regulatory contrivance: Regulatory T cell development and the forkhead family transcription factor Foxp3, Nat Immunol, 10.1038/ni1179 Hori, 2017, Control of regulatory T cell development by the transcription factor Foxp3, J Immunol Kim, 2007, Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice, Nat Immunol, 10.1038/ni1428 Malek, 2002, CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rβ-deficient mice: Implications for the nonredundant function of IL-2, Immunity, 10.1016/S1074-7613(02)00367-9 Van Puijvelde, 2006, Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis, Circulation, 10.1161/CIRCULATIONAHA.106.615609 Van Puijvelde, 2007, Induction of oral tolerance to HSP60 or an HSP60-peptide activates t cell regulation and reduces atherosclerosis, Arterioscler Thromb Vasc Biol, 10.1161/ATVBAHA.107.151274 Cheng, 2008, The Th17/Treg imbalance in patients with acute coronary syndrome, Clin Immunol, 10.1016/j.clim.2008.01.009 Jovanovic, 2001, Modulation of TIMP-1 synthesis by antiinflammatory cytokines and prostaglandin E2 in interleukin 17 stimulated human monocytes/macrophages, J Rheumatol Jovanovic, 1998, IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages, J Immunol, 160, 3513, 10.4049/jimmunol.160.7.3513 Koenders, 2005, Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis, Arthritis Rheum, 52, 3239, 10.1002/art.21342 Csiszar, 2004, Synergistic effects of vascular IL-17 and TNFα may promote coronary artery disease, Med Hypotheses Taleb, 2015, IL-17 and Th17 cells in atherosclerosis: Subtle and contextual roles, Arterioscler Thromb Vasc Biol, 10.1161/ATVBAHA.114.303567 Caligiuri, 2002, Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice, J Clin Investig, 10.1172/JCI7272 Binder, 2005, Natural antibodies and the autoimmunity of atherosclerosis, Springer Semin Immunopathol, 10.1007/s00281-004-0185-z Binder, 2003, Pneumococcal vaccination decreases atherosclerotic lesion formation: Molecular mimicry between Streptococcus pneumoniae and oxidized LDL, Nat Med, 10.1038/nm876 Major, 2002, B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice, Arterioscler Thromb Vasc Biol, 10.1161/01.ATV.0000039169.47943.EE Michael Munro, 1987, An immunohistochemical analysis of human aortic fatty streaks, Hum Pathol, 10.1016/S0046-8177(87)80168-5 Le Borgne, 2015, Once Upon a Time: The Adaptive Immune Response in Atherosclerosis—a Fairy Tale No More, Mol Med, 10.2119/molmed.2015.00027 Lipscomb, 2015, Dendritic Cells: Immune Regulators in Health and Disease, Physiol Rev Zernecke, 2008, Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis, Circ Res, 10.1161/CIRCRESAHA.107.160697 Wick, 2018, Atherosclerosis, autoimmunity, and vascular-associated lymphoid tissue, FASEB J Mozaffarian, 2016, Executive summary: Heart disease and stroke statistics-2016 update: A Report from the American Heart Association, Circulation Shah, 2014, Vaccine for atherosclerosis, J Am Coll Cardiol, 10.1016/j.jacc.2014.10.018 García-González, 2015, Reality of a Vaccine in the Prevention and Treatment of Atherosclerosis, Arch Med Res, 10.1016/j.arcmed.2015.06.004 Oviedo Orta, 2005, Inmunomodulacion: un nuevo enfoque terapeutico para el tratamiento de la atherosclerosis, Rev Arg Cir Cardiovasc, 3, 159e166 Rittershaus, 2007, Vaccines for cholesterol management, World J Surg, 10.1007/s00268-006-0759-0 Janeway, 2013, Pillars article: approaching the asymptote? Evolution and revolution in immunology. Cold spring harb symp quant biol 1989. 54: 1-13, J Immunol Brewer, 1997, Cytokines and the mechanisms of action of vaccine adjuvants, Cytokines Cell Mol Ther Guo, 2015, Inflammasomes: Mechanism of action, role in disease, and therapeutics, Nat Med, 10.1038/nm.3893 Nossal, 1999, Vaccines, 1387 Pasquale, 2015, Vaccine Adjuvants: from 1920 to 2015 and Beyond, Vaccines, 3, 320, 10.3390/vaccines3020320 Mallat, 2004, Immunomodulation to combat atherosclerosis: the potential role of immune regulatory cells, Expert Opin Biol Ther, 10.1517/14712598.4.9.1387 Fredrikson, 2003, Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease, Arterioscler Thromb Vasc Biol, 10.1161/01.ATV.0000067935.02679.B0 Frederikson, 2005, Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression, Autoimmunity, 10.1080/08916930500050525 Chyu, 2005, Immunization using an Apo B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apo E (-/-) mice, Biochem Biophys Res Commun, 10.1016/j.bbrc.2005.10.141 Fredrikson, 2008, Treatment with apo B peptide vaccines inhibits atherosclerosis in human apo B-100 transgenic mice without inducing an increase in peptide-specific antibodies, J Intern Med, 10.1111/j.1365-2796.2008.01995.x Klingenberg, 2010, Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis, Arterioscler Thromb Vasc Biol, 10.1161/ATVBAHA.109.202671 Wigren, 2011, Evidence for a role of regulatory T cells in mediating the atheroprotective effect of apolipoprotein B peptide vaccine, J Intern Med, 10.1111/j.1365-2796.2010.02311.x Herbin, 2012, Regulatory T-cell response to apolipoprotein B100-derived peptides reduces the development and progression of atherosclerosis in mice, Arterioscler Thromb Vasc Biol, 10.1161/ATVBAHA.111.242800 Chyu, 2012, CD8 + T cells mediate the athero-protective effect of immunization with an ApoB-100 peptide, PLoS One Tse, 2013, Atheroprotective vaccination with MHC-II restricted peptides from ApoB-100, Front Immunol, 10.3389/fimmu.2013.00493 Zhu, 2014, Immunization with advanced glycation end products modified low density lipoprotein inhibits atherosclerosis progression in diabetic apoE and LDLR null mice, Cardiovasc Diabetol, 10.1186/s12933-014-0151-6 Zhang, 2012, A novel atherogenic epitope from Mycobacterium tuberculosis heat shock protein 65 enhances atherosclerosis in rabbit and LDL receptor-deficient mice, Heart Vessels, 10.1007/s00380-011-0183-8 Habets, 2010, Vaccination using oxidized low-density lipoprotein-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice, Cardiovasc Res, 10.1093/cvr/cvp338 Zhou, 2001, LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis, Arterioscler Thromb Vasc Biol, 10.1161/01.ATV.21.1.108 Chyu, 2004, Timing affects the efficacy of LDL immunization on atherosclerotic lesions in apo e (-/-) mice, Atherosclerosis, 10.1016/j.atherosclerosis.2004.04.016 Zhou, 2005, Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis, Circ Res, 10.1161/01.RES.0000156889.22364.f1 George, 1998, Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis, Atherosclerosis, 10.1016/S0021-9150(98)00015-X Liaw, 2014, A vaccine targeted at CETP alleviates high fat and high cholesterol diet-induced atherosclerosis and non-alcoholic steatohepatitis in rabbit, PLoS One, 10.1371/journal.pone.0111529 Gaofu, 2005, Vaccinating rabbits with a cholesteryl ester transfer protein (CETP) B-cell epitope carried by heat shock protein-65 (HSP65) for inducing anti-CETP antibodies and reducing aortic lesions in vivo, J Cardiovasc Pharmacol, 10.1097/01.fjc.0000161402.91456.70 Mao, 2006, Intramuscular immunization with a DNA vaccine encoding a 26-amino acid CETP epitope displayed by HBc protein and containing CpG DNA inhibits atherosclerosis in a rabbit model of atherosclerosis, Vaccine, 10.1016/j.vaccine.2006.03.082 Jun, 2012, Effects of nasal immunization of multi-target preventive vaccines on atherosclerosis, Vaccine, 10.1016/j.vaccine.2011.12.043 Davidson, 2003, The safety and immunogenicity of a CETP vaccine in healthy adults, Atherosclerosis, 10.1016/S0021-9150(03)00137-0 Galabova, 2014, Peptide-based anti-PCSK9 vaccines-an approach for long-term LDLc management, PLoS One, 10.1371/journal.pone.0114469 Pan, 2017, A Therapeutic Peptide Vaccine Against PCSK9, Sci Rep, 10.1038/s41598-017-13069-w Landlinger, 2017, The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE∗3Leiden.CETP mice, Eur Heart J, 38, 2499, 10.1093/eurheartj/ehx260 Samson, 2012, Immune Response to Lipoproteins in Atherosclerosis, Cholesterol, 10.1155/2012/571846 Podrez, 1999, Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro, J Clin Investig, 10.1172/JCI5549 Moguilevsky, 2004, Monoclonal antibodies against LDL progressively oxidized by myeloperoxidase react with ApoB-100 protein moiety and human atherosclerotic lesions, Biochem Biophys Res Commun, 10.1016/j.bbrc.2004.08.220 Yamaguchi, 2006, Elevated circulating levels of markers of oxidative-nitrative stress and inflammation in a genetic rat model of metabolic syndrome, Nitric Oxide Biol Chem, 10.1016/j.niox.2006.04.264 Nambi, 2005, The use of myeloperoxidase as a risk marker for atherosclerosis, Curr Atheroscler Rep, 10.1007/s11883-005-0035-z Slot, 2007, Anti-oxidized low-density lipoprotein antibodies in myeloperoxidase- positive vasculitis patients preferentially recognize hypochlorite-modified low density lipoproteins, Clin Exp Immunol, 10.1111/j.1365-2249.2007.03420.x van Leeuwen, 2009, The therapeutic potential of targeting B cells and anti-oxLDL antibodies in atherosclerosis, Autoimmun Rev, 10.1016/j.autrev.2009.03.001 Van Leeuwen, 2009, The IgM response to modified LDL in experimental atherosclerosis: Hypochlorite-modified LDL IgM antibodies versus classical natural T15 IgM antibodies, Ann N Y Acad Sci, 10.1111/j.1749-6632.2009.04657.x Rouhl, 2010, Autoantibodies against oxidized low-density lipoprotein in cerebral small vessel disease, Stroke, 10.1161/STROKEAHA.110.592725 Salonen, 1992, Autoantibody against oxidised LDL and progression of carotid atherosclerosis, Lancet, 10.1016/0140-6736(92)90926-T Virella, 1993, Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers, Int J Clin Lab Res, 10.1007/BF02592290 Fukumoto, 2000, Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population, Arterioscler Thromb Vasc Biol, 10.1161/01.ATV.20.3.703 Shoji, 2000, Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects, Atherosclerosis, 10.1016/S0021-9150(99)00218-X Schiopu, 2004, Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis, Circulation, 10.1161/01.CIR.0000143162.56057.B5 Nicolo, 2003, Reduction of Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice by Passive Administration of Antiphospholipid Antibody, Arthritis Rheum, 10.1002/art.11255 George, 1999, Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65, Arterioscler Thromb Vasc Biol, 10.1161/01.ATV.19.3.505 George, 1999, Immunolocalization of β2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: Potential implications for lesion progression, Circulation, 10.1161/01.CIR.99.17.2227 Bergmark, 1995, Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL, Arterioscler Thromb Vasc Biol, 10.1161/01.ATV.15.4.441 Monaco, 2001, Autoantibodies against oxidized low density lipoproteins in patients with stable angina, unstable angina or peripheral vascular disease: Pathophysiological implications, Eur Heart J, 10.1053/euhj.2000.2554 Fredrikson, 2007, Association between IgM against an aldehyde-modified peptide in apolipoprotein B-100 and progression of carotid disease, Stroke, 10.1161/STROKEAHA.106.474577 Hulthe, 1998, Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia, Arterioscler Thromb Vasc Biol, 10.1161/01.ATV.18.8.1203 Wu, 2003, Anti-idiotypes to oxidized LDL antibodies in intravenous immunoglobulin preparations - Possible immunomodulation of atherosclerosis, Autoimmunity, 10.1080/0891693031000080228 Schiopu, 2007, Recombinant Antibodies to an Oxidized Low-Density Lipoprotein Epitope Induce Rapid Regression of Atherosclerosis in Apobec-1-/-/Low-Density Lipoprotein Receptor-/- Mice, J Am Coll Cardiol, 10.1016/j.jacc.2007.07.081 Ley, 2016, 2015 russell ross memorial lecture in vascular biology: Protective autoimmunity in atherosclerosis, Arterioscler Thromb Vasc Biol, 10.1161/ATVBAHA.115.306009 Barter, 2007, Effects of Torcetrapib in Patients at High Risk for Coronary Events, N Engl J Med, 10.1056/NEJMoa0706628 Barter, 2000, CETP and atherosclerosis, Arterioscler Thromb Vasc Biol, 10.1161/01.ATV.20.9.2029 Rittershaus, 2000, Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis, Arterioscler Thromb Vasc Biol, 10.1161/01.ATV.20.9.2106 Nicholls, 2008, Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: Insights from illustrate (investigation of lipid level management using coronary ultrasound to assess reduction of atherosclerosi, Circulation, 10.1161/CIRCULATIONAHA.108.790733 Nissen, 2007, Effect of Torcetrapib on the Progression of Coronary Atherosclerosis, N Engl J Med, 10.1056/NEJMoa070635 Oliveira, 2011, Cholesteryl ester transfer protein: The controversial relation to atherosclerosis and emerging new biological roles, IUBMB Life, 10.1002/iub.448 Denis, 2012, Gene Inactivation of PCSK9 Reduces Atherosclerosis in Mice, Circulation, 10.1161/CIRCULATIONAHA.111.057406 Rashid, 2005, Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9, Proc Natl Acad Sci, 10.1073/pnas.0501652102 Zaid, 2008, Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration, Hepatology, 10.1002/hep.22354 Chaudhary, 2017, PCSK9 inhibitors: A new era of lipid lowering therapy, World J Cardiol, 10.4330/wjc.v9.i2.76 Crossey, 2015, A cholesterol-lowering VLP vaccine that targets PCSK9, Vaccine, 10.1016/j.vaccine.2015.09.044 Bocksch, 2007, C-terminal apolipoprotein E-derived peptide, Ep1.B, displays anti-atherogenic activity, Atherosclerosis, 10.1016/j.atherosclerosis.2006.10.014 Bellemore, 2014, Anti-atherogenic peptide Ep1.B derived from apolipoprotein E induces tolerogenic plasmacytoid dendritic cells, Clin Exp Immunol, 10.1111/cei.12370 Almanzar, 2012, Autoreactive HSP60 epitope-specific T-cells in early human atherosclerotic lesions, J Autoimmun, 10.1016/j.jaut.2012.07.006 Grundtman, 2011, Heat shock protein 60 and immune inflammatory responses in atherosclerosis, Arterioscler Thromb Vasc Biol, 10.1161/ATVBAHA.110.217877 Grundtman, 2011, The autoimmune concept of atherosclerosis, Curr Opin Lipidol, 10.1097/MOL.0b013e32834aa0c2 Kilic, 2012, Heat Shock Proteins: Pathogenic Role in Atherosclerosis and Potential Therapeutic Implications, Autoimmune Dis, 1 Kleindienst, 1993, Immunology of atherosclerosis. Demonstration of heat shock protein 60 expression and T lymphocytes bearing alpha/beta or gamma/delta receptor in human atherosclerotic lesions, Am J Pathol Benagiano, 2014, Human 60-kDa Heat Shock Protein Is a Target Autoantigen of T Cells Derived from Atherosclerotic Plaques, J Immunol Foteinos, 2005, Anti-heat shock protein 60 autoantibodies induce atherosclerosis in apolipoprotein E-deficient mice via endothelial damage, Circulation, 10.1161/CIRCULATIONAHA.105.547414 Chyu, 2017, Vaccine against arteriosclerosis: an update, Ther Adv Vaccines, 10.1177/2051013617693753 Long, 2012, Nasal immunization with different forms of heat shock protein-65 reduced high-cholesterol-diet-driven rabbit atherosclerosis, Int Immunopharmacol, 10.1016/j.intimp.2012.03.008 Briles, 2004, Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae, J Exp Med Yother, 1982, Protection of mice from infection with Streptococcus pneumoniae by anti-phosphocholine antibody, Infect Immun, 10.1128/IAI.36.1.184-188.1982 Lam, 2010, Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: A prospective cohort study, Clin Infect Dis Lamontagne, 2008, Pneumococcal vaccination and risk of myocardial infarction, CMAJ, 10.1503/cmaj.070221 Siriwardena, 2010, Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: Matched case - Control study, CMAJ, 10.1503/cmaj.091891 Tseng, 2010, Pneumococcal vaccination and risk of acute myocardial infarction and stroke in men, JAMA J Am Med Assoc, 303, 1699, 10.1001/jama.2010.529 Vlachopoulos, 2015, Association between pneumococcal vaccination and cardiovascular outcomes: A systematic review and meta-analysis of cohort studies, Eur J Prev Cardiol, 10.1177/2047487314549512 Tissot, 2013, A VLP-based vaccine against interleukin-1α protects mice from atherosclerosis, Eur J Immunol, 10.1002/eji.201242687 van Es, 2011, IL-15 aggravates atherosclerotic lesion development in LDL receptor deficient mice, Vaccine, 10.1016/j.vaccine.2010.11.037 Pflanz, 2002, IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+T cells, Immunity, 10.1016/S1074-7613(02)00324-2 Batten, 2006, Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells, Nat Immunol, 10.1038/ni1375 Fitzgerald, 2007, Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis, J Immunol, 179, 3268, 10.4049/jimmunol.179.5.3268 Goldberg, 2014, Suppression of Ongoing Experimental Autoimmune Encephalomyelitis by Neutralizing the Function of the p28 Subunit of IL-27, J Immunol Goldberg, 2014, Suppression of Ongoing Adjuvant-Induced Arthritis by Neutralizing the Function of the p28 Subunit of IL-27, J Immunol Ferrara, 2003, The biology of VEGF and its receptors, Nat Med, 10.1038/nm0603-669 Belgore, 2004, Localisation of members of the vascular endothelial growth factor (VEGF) family and their receptors in human atherosclerotic arteries, J Clin Pathol, 10.1136/jcp.2003.012419 Moulton, 2001, Plaque angiogenesis and atherosclerosis, Curr Atheroscler Rep, 10.1007/s11883-001-0065-0 Hauer, 2007, Vaccination against VEGFR2 attenuates initiation and progression of atherosclerosis, Arterioscler Thromb Vasc Biol, 10.1161/ATVBAHA.107.143743 Dunér, 2011, Immunization of apoE -/- mice with aldehyde-modified fibronectin inhibits the development of atherosclerosis, Cardiovasc Res, 10.1093/cvr/cvr101 Skålén, 2002, Subendothelial retention of atherogenic lipoproteins in early atherosclerosis, Nature, 10.1038/nature00804 Gustafsson, 2004, Mechanism of lipoprotein retention by the extracellular matrix, Curr Opin Lipidol, 10.1097/00041433-200410000-00003 Greilberger, 1997, In vitro interactions of oxidatively modified LDL with type I, II, III, IV, and V collagen, laminin, fibronectin, and poly-D-lysine, Arterioscler Thromb Vasc Biol, 10.1161/01.ATV.17.11.2721 van der Hoek, 2011, Binding of recombinant apolipoprotein(a) to extracellular matrix proteins, Arterioscler Thromb A J Vasc Biol, 14, 1792, 10.1161/01.ATV.14.11.1792 Dunér, 2009, Immune responses against fibronectin modified by lipoprotein oxidation and their association with cardiovascular disease, J Intern Med, 10.1111/j.1365-2796.2008.02067.x George, 2000, Adoptive transfer of β2-glycoprotein i-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice, Circulation, 10.1161/01.CIR.102.15.1822 De Haro, 2015, Attenuation of early atherosclerotic lesions by immunotolerance with β2 glycoprotein i and the immunomodulatory effectors interleukin 2 and 10 in a murine model, J Vasc Surg, 10.1016/j.jvs.2014.05.096 Hasunuma, 2003, Involvement of beta2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages, Clin Exp Immunol Ippel, 2009, Structure of the tyrosine-sulfated C5a receptor N terminus in complex with chemotaxis inhibitory protein of Staphylococcus aureus, J Biol Chem, 10.1074/jbc.M808179200 Haskard, 2008, The role of complement in atherosclerosis, Curr Opin Lipidol, 10.1097/MOL.0b013e32830f4a06 Meuwissen, 2006, Colocalisation of intraplaque C reactive protein, complement, oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction, J Clin Pathol, 10.1136/jcp.2005.027235 Lu, 2012, Immunization with a combination of 2 peptides derived from the c5a receptor significantly reduces early atherosclerotic lesion in ldlrtm1her Apobtm2Sgy j mice, Arterioscler Thromb Vasc Biol, 10.1161/ATVBAHA.112.253179 Laere, 2016, Plant-based vaccines: Production and challenges, J Bot Guan, 2013, Recent advances and safety issues of transgenic plant-derived vaccines, Appl Microbiol Biotechnol, 10.1007/s00253-012-4566-2 Salazar-González, 2013, A perspective for atherosclerosis vaccination: Is there a place for plant-based vaccines?, Vaccine, 10.1016/j.vaccine.2013.01.005 Synetos, 2017, Atherosclerosis and inflammation. Clinical aspects of a modern tale, Hellenic J Cardiol, 58, 122, 10.1016/j.hjc.2017.05.013 Vlachopoulos, 2018, Relationship of PCSK9 levels with indices of vascular function and subclinical atherosclerosis in patients with familial dyslipidemias, Hellenic J Cardiol, 60, 124, 10.1016/j.hjc.2018.05.003 Tsikas, 2018, Associations between asymmetric dimethylarginine (ADMA), nitrite-dependent renal carbonic anhydrase activity, and plasma testosterone levels in hypogonadal men, Hellenic J Cardiol, 59, 201, 10.1016/j.hjc.2017.10.004